Comments
Loading...

Akebia Therapeutics

AKBANASDAQ
Logo brought to you by Benzinga Data
$1.40
0.053.70%
Pre-Market: 4:36 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$7.50
Lowest Price Target1
$2.00
Consensus Price Target1
$3.90

Akebia Therapeutics (NASDAQ:AKBA) Stock, Analyst Ratings, Price Targets, Forecasts

Akebia Therapeutics Inc has a consensus price target of $3.9 based on the ratings of 6 analysts. The high is $7.5 issued by HC Wainwright & Co. on September 6, 2024. The low is $2 issued by Needham on May 9, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on September 6, 2024, August 12, 2024, and March 28, 2024, respectively. With an average price target of $7 between HC Wainwright & Co., there's an implied 400.00% upside for Akebia Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
BTIG
Piper Sandler
Needham
Mizuho

1calculated from analyst ratings

Analyst Ratings for Akebia Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Akebia Therapeutics (AKBA) stock?

A

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $7.50 expecting AKBA to rise to within 12 months (a possible 435.71% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Akebia Therapeutics (AKBA)?

A

The latest analyst rating for Akebia Therapeutics (NASDAQ:AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Akebia Therapeutics (AKBA)?

A

The last upgrade for Akebia Therapeutics Inc happened on August 28, 2023 when HC Wainwright & Co. raised their price target to $3.75. HC Wainwright & Co. previously had a neutral for Akebia Therapeutics Inc.

Q

When was the last downgrade for Akebia Therapeutics (AKBA)?

A

The last downgrade for Akebia Therapeutics Inc happened on March 31, 2022 when HC Wainwright & Co. changed their price target from $10 to $2 for Akebia Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

Q

Is the Analyst Rating Akebia Therapeutics (AKBA) correct?

A

While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a reiterated with a price target of $7.50 to $7.50. The current price Akebia Therapeutics (AKBA) is trading at is $1.40, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch